Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.
Adding corticosteroids to standard intravenous (IV) immunoglobulin treatment for children with Kawasaki disease judged to be at higher risk of developing blood vessel complications made initial treatment more successful and prevented these complications.
Researchers have uncovered how the immune system is altered in a rare COVID-19 related illness in children referred to as paediatric inflammatory multisystem syndrome (PIMS-TS).
Many scientists have explored the use of new as well as already approved drugs for this condition, and one of the very few promising leads is dexamethasone. Dexamethasone is a corticosteroid, which has been reported in some earlier studies to reduce mortality in these patients by 18% and 36% in COVID-19 patients who are on oxygen and ventilators, respectively.
The COVID-19 pandemic has taken the lives of several hundred thousand people across the world. In Spain, a intense outbreak took a toll of over 28,000 lives.
As COVID-19 continues to spread over the world scientists continue to seek the reasons for the difference in disease severity from person to person.
Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye.
Now, an intriguing new study out of the University of Wisconsin-Milwaukee reveals that numerous small molecule drugs like the proton pump inhibitors omeprazole and rabeprazole bind the important Mac1 domain on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.
QUT researchers are collaborating with colleagues at the University of Oxford on a UK clinical trial to test common asthma inhalers as a treatment for COVID-19 infection.
Researchers from Queensland University of Technology and Oxford University are working in collaboration to begin human clinical trials of inhaled corticosteroids, commonly used for asthma patients, on patients with COVID-19. The researchers believe that this could be useful for patients with the novel coronavirus infection.
A new study published on the preprint server medRxiv in July 2020 describes the organ and tissue-specific spread of the virus causing the current COVID-19 pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Now, a recent trial published on the preprint server medRxiv* in July 2020 reports that a majority of hospitalized COVID-19 patients have a high titer of neutralizing antibodies, at the time of admission, within 10 days of symptomatic disease.
A study conducted by UK researchers has found no evidence to support the hypothesis that regular use of inhaled corticosteroids may have a beneficial effect on mortality outcomes among patients with coronavirus disease 2019 (COVID-19).
Now a new study by an Italian team of researchers published in June 2020 on the preprint server medRxiv reports that potassium levels are often low in COVID-19 disease, mostly due to the urinary loss of potassium.
Results from Oxford University’s RECOVERY trial into existing drugs for the treatment of COVID-19 has found that dexamethasone reduced deaths by a third in ventilated coronavirus patients and by a fifth in coronavirus patients requiring oxygen. This is the first drug of its kind to be demonstrated to have a significant impact on COVID-19 mortality.
Researchers at the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute have identified a key enzyme that contributes to eczema, which may lead to better treatment to prevent the skin disorder's debilitating effects.
ANCA-associated vasculitis (AAV) is a systemic disease involving the formation of special autoantibodies (so-called anti-neutrophil cytoplasmic antibodies/ANCA) and vascular inflammation.
The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Octapharma USA for a phase three clinical trial on the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression.
Researchers at Wayne State University and Henry Ford Health System in Michigan have conducted a study indicating that the corticosteroid methylprednisolone could improve outcomes among patients with severe coronavirus disease 2019 (COVID-19).
Maternal antenatal corticosteroid treatment is standard care when there is a risk for preterm delivery. The treatment improves the prognosis of babies born preterm.
Korean researchers have screened 48 FDA-approved drugs against SARS-CoV-2, and found that two, that are already FDA-approved for other illnesses, seem promising.